Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
Stefano Fagiuoli,1 Pierluigi Toniutto,2 Nicola Coppola,3 Domenica Daniela Ancona,4 Margherita Andretta,5 Fausto Bartolini,6 Fulvio Ferrante,7 Alessandro Lupi,8 Stefano Palcic,9 Francesca Vittoria Rizzi,10 Davide Re,11 Gema Alvarez Nieto,12 Candido Hernandez,13 Francesca Frigerio,14 Valentina Perrone...
Main Authors: | Fagiuoli S, Toniutto P, Coppola N, Ancona DD, Andretta M, Bartolini F, Ferrante F, Lupi A, Palcic S, Rizzi FV, Re D, Alvarez Nieto G, Hernandez C, Frigerio F, Perrone V, Degli Esposti L, Mangia A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-01-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/italian-real-world-analysis-of-the-impact-of-polypharmacy-and-aging-on-peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Hepatitis C: A Pharmacological Therapeutic Update
by: Sonia Santander Ballestín, et al.
Published: (2021-04-01) -
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
by: A. Maughan, et al.
Published: (2019-05-01) -
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C
by: Jyh-Jou Chen, et al.
Published: (2022-11-01) -
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
by: Desmond Y. H. Yap, et al.
Published: (2020-10-01) -
DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
by: Kamila Abram, et al.
Published: (2023-02-01)